Theriva Biologics Inc (TOVX) concluded trading on Wednesday at a closing price of $0.81, with 45.9 million shares of worth about $37.18 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -59.30% during that period and on May 07, 2025 the price saw a loss of about -40.44%. Currently the company’s common shares owned by public are about 2.78M shares, out of which, 2.75M shares are available for trading.
Stock saw a price change of -40.00% in past 5 days and over the past one month there was a price change of -22.86%. Year-to-date (YTD), TOVX shares are showing a performance of -53.71% which decreased to -91.96% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.96 but also hit the highest price of $12.28 during that period. The average intraday trading volume for Theriva Biologics Inc shares is 31.43K. The stock is currently trading -38.52% below its 20-day simple moving average (SMA20), while that difference is down -35.99% for SMA50 and it goes to -62.53% lower than SMA200.
Theriva Biologics Inc (AMEX: TOVX) currently have 2.78M outstanding shares and institutions hold larger chunk of about 1.24% of that.
The stock has a current market capitalization of $2.25M and its 3Y-monthly beta is at 1.11. It has posted earnings per share of -$26.66 in the same period. It has Quick Ratio of 2.15 while making debt-to-equity ratio of 0.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TOVX, volatility over the week remained 23.42% while standing at 13.10% over the month.
Stock’s fiscal year EPS is expected to rise by 70.99% while it is estimated to decrease by -4.71% in next year. EPS is likely to shrink at an annualized rate of 36.86% for next 5-years, compared to annual growth of 39.99% made by the stock over the past 5-years.
